Immunotherapy with allogenic super-charged NK cells appears a promising therapeutic approach in the treatment of GBM by selectively killing malignant cancer stem-like cell population, and increasing their immune-related surface markers (MHC class I and CD54) as well as their susceptibility to chemotherapy (Fig. 6k). This evidence concerns the gene ICAM1 and cancer.